Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin added to 10-day decitabine in unfit adults with AML or high-risk MDS
NL-OMON60319Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of midostaurin and decitabine, sponsored by HOVON. Started Dec 2019; status: active, not recruiting.
02
Drugs
midostaurindecitabine
Beyond the preview
Go deeper on NL-OMON60319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60319.